Comparing Ogivri vs Taxotere
| Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
|---|
| Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer - Adjuvant, Esophageal Carcinoma, Breast Cancer, Gastric Cancer. Ogivri may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer, Breast Cancer, Gastric Cancer, Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Head and Neck Cancer. Taxotere may also be used for purposes not listed in this... View more |
Related suggestions Breast Cancer
Gastric Cancer
|
|||||||
| More about Ogivri (trastuzumab) | More about Taxotere (docetaxel) | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Taxotere has an average rating of 5.2 out of 10 from a total of 11 ratings on Drugs.com. 36% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Ogivri side effects |
View all Taxotere side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Ogivri prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
| Other trastuzumab brands include: Herceptin, Hercessi, Herzuma, Kanjinti, Ontruzant, Trazimera | Other docetaxel brands include: Docivyx | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
924 hours |
11.1 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 191 drugs are known to interact with Ogivri:
|
A total of 520 drugs are known to interact with Taxotere:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
December 01, 2017 |
May 14, 1996 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.